Table 2.
Results of included studies.
| Authors | Sample size | Male | Median/Mean age | pCR | MPR | R0 resection rate | Incidence of ≥ grade 3 TRAEs | Neoadjuvant therapy completion rate | Surgical resection rate | Surgical delay rate | Whether all patients reached surgery time |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cower, D., et al. (19) | 36 | NA | NA | 8/33 | 22/33 | NA | NA | NA | 33/36 | NA | yes |
| Jiang, N., et al. (23) | 23 | NA | NA | 11/20 | 16/20 | NA | 16/23 | 21/23 | 20/23 | NA | yes |
| Kelly, R. J., et al. (32) | 32 | 81% | 65 | 9/31 | 16/31 | NA | NA | NA | 31/32 | NA | not mentioned |
| Lee, S., et al. (33) | 28 | 89% | 60 | 6/26 | NA | 25/26 | NA | NA | 26/28 | NA | yes |
| Li, C., et al. (12) | 20 | 95% | 62 | 10/18 | 16/18 | 17/18 | 13/20 | 19/20 | 18/20 | 0 | yes |
| Manish A. Shah, et al. (39) | 40 | 80% | 68 | NA | 15/31 | NA | NA | NA | NA | NA | no |
| Uboha, NV., et al. (25) | 22 | 91% | 64 | 5/19 | NA | 15/19 | NA | NA | 19/22 | NA | yes |
| Qi, W.X., et al. (41) | 20 | 95% | 61.2 | 9/14 | NA | NA | 3/20 | NA | 14/20 | NA | no |
| van Den Ende, T., et al. (13) | 40 | 88% | 63 | 10/33 | NA | 33/33 | 17/40 | 34/40 | 33/40 | 0 | yes |
| Xu, X., et al. (28) | 20 | NA | NA | 7/13 | 10/13 | NA | 7/13 | NA | 13/10 | NA | no |
| Duan, H., et al. (29) | 23 | 91% | 63.5 | 6/17 | 9/17 | 16/17 | 7/23 | 21/23 | 17/23 | 0 | yes |
| Gao, L., et al. (20) | 20 | 85% | 58.3 | 2/12 | 5/12 | 12/12 | NA | 20/20 | 12/20 | 0 | yes |
| Gu, Y., et al. (30) | 17 | 76% | 65 | 4/15 | 8/15 | 15/15 | 6/17 | 17/17 | 15/17 | NA | no |
| Guo, J., et al. (21) | 15 | NA | NA | NA | 6/11 | 11/11 | NA | NA | 11/15 | 0 | yes |
| He, W., et al. (31) | 20 | 75% | 61.4 | 3/16 | 7/16 | 14/16 | 4/20 | 18/20 | 16/20 | 0 | yes |
| Jiang, B., et al. (22) | 10 | NA | NA | 4/10 | 6/10 | 10/10 | NA | NA | 10/10 | 0 | yes |
| Li, K., et al. (34) | 17 | 94% | 64 | 2/12 | 7/12 | 12/12 | 2/17 | NA | 12/17 | 0 | yes |
| Li, Z., et al. (24) | 20 | 80% | NA | 3/20 | 7/20 | 20/20 | 2/20 | NA | 20/20 | NA | yes |
| Liu, D., et al. (35) | 23 | NA | NA | 6/18 | NA | 18/18 | 2/23 | NA | 18/23 | NA | yes |
| Liu, J.; Li, J., et al. (36) | 56 | 75% | 61 | 16/51 | 30/51 | 51/51 | 6/56 | 51/56 | 51/56 | NA | yes |
| Liu, J.; Yang, Y., et al. (37) | 60 | 83% | 65 | 20/51 | 35/51 | 50/51 | 34/60 | 55/60 | 51/60 | 8/60 | yes |
| Ma, J., et al. (38) | 42 | NA | 63 | 6/16 | NA | NA | NA | NA | 16/42 | NA | no |
| Shang, X.,et al. (42) | 49 | NA | NA | 12/29 | 21/29 | 29/29 | 0/29 | NA | 29/42 | 0 | no |
| Shen, D., et al. (43) | 28 | 96% | 62.2 | 9/28 | NA | 26/27 | 2/28 | 28/28 | 27/28 | 0 | yes |
| Wang, F., et al. (55) | 26 | 65% | 63 | 3/12 | 5/12 | 12/12 | 1/26 | 17/26 | 12/17 | NA | no |
| Wang, W., et al. (26) | 27 | NA | NA | 4/14 | NA | 14/14 | NA | 24/27 | 14/27 | NA | no |
| Wang, Z., et al. (44) | 30 | 80% | 62 | 7/29 | 15/29 | NA | 11/30 | 29/30 | 29/30 | 5/30 | yes |
| Xing, W., et al. (45) | 30 | 73% | experiment group:63.8; control group:63.13 | 5/24 | NA | 24/24 | NA | NA | 24/30 | NA | yes |
| Xu, W., et al. (56) | 46 | NA | NA | 8/37 | 18/37 | 37/37 | 7/46 | 45/46 | 37/46 | NA | not mentioned |
| Yamamoto, S.; Matsuda, S., et al. (40, 46) | 25 | NA | cohort A&B:62; cohort C&D:60 | 6/25 | NA | 23/25 | NA | 25/25 | 25/25 | 0 | yes |
| Yan, X., et al. (47) | 45 | NA | NA | 18/36 | 26/36 | NA | 15/45 | NA | 36/45 | NA | yes |
| Yang, P., et al. (48) | 16 | 88% | 60.5 | 5/16 | NA | 15/16 | NA | NA | 16/16 | NA | yes |
| Yang, W., et al. (49) | 23 | 96% | 58.6 | 5/20 | 10/20 | 20/20 | NA | 23/23 | 20/23 | 0 | yes |
| Zhang, G., et al. (50) | 24 | NA | NA | 3/18 | 9/18 | NA | NA | NA | 18/24 | NA | no |
| Zhang, X (51). | 25 | NA | NA | 8/25 | 16/25 | NA | 2/25 | NA | 25/25 | 0 | yes |
| Zhang, Y., et al. (52) | 166 | 84% | 62.9 | 15/81 | 51/81 | 9/82 | 13/166 | NA | 82/166 | NA | no |
| Zhang, Z.; Hong, Z., et al. (53) | 30 | 87% | 58.3 | 4/23 | 12/23 | 23/23 | 1/30 | 30/30 | 23/30 | 0 | yes |
| Zhang, Z.; Ye, J., et al. (54) | 40 | NA | NA | 10/40 | 19/40 | 39/40 | NA | NA | NA | 0 | yes |
pCR, pathological complete response; MPR, major pathological response; TRAEs, treatment-related adverse events. NA, not available.